As the nation grapples with the overdose epidemic, the legal battle surrounding Purdue Pharma's bankruptcy immunity has taken center stage.
Read moreWhile the rhetoric surrounding closing the border may seem appealing, it is essential to critically analyze the potential consequences.
Read moreThe Senate Committee on Health, Education, Labor, and Pensions is scheduled to consider the Modernizing Opioid Treatment Access Act (MOTAA).
Read moreDr. Ruan explains how biased jury instructions can lead to biased outcomes in criminal cases involving physicians' prescribing behavior.
Read moreAlthough Dr. Sasaki didn’t know what was actually going on, he became suspicious after another doctor told him that something...
Read moreI have spent the past thirteen years navigating the healthcare system like many who become disabled due to high-impact chronic...
Read moreIt feels like vaccines are everywhere. Every news cycle seems to introduce a new vaccine or vaccine formulary. But how...
Read moreWe have until Dec 4th to submit professional comments on the DEA’s proposed 2024 controlled substances production quota cuts.
Read moreWe share our experiences reaching out to and speaking with federal and state legislators while offering nuggets of advice and...
Read moreThe Illinois state assembly should support IL HB 2046, which requires a warrant prior to investigating a provider’s prescription database.
Read moreWhen asked whether we would publish his writings, we responded yes. Here was a man we knew nothing about, but...
Read moreWe review the history of healthcare law to see why the original laws were framed as oaths to guide physician...
Read moreClinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read moreDaily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.
Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.
© 2026 Daily Remedy
© 2026 Daily Remedy